• Researcher Profile

    Julia S. Wong, MD

     
    Julia S. Wong, MD

     
    Institute Physician

    Assistant Professor of Radiation Oncology, Harvard Medical School

    Centers/Programs

    Breast Oncology
    Thoracic Oncology
    Radiation Oncology

    Office phone: 617-632-3591
    Fax: 617-632-4247
    Email: jwong@lroc.harvard.edu

    Preferred contact method: office phone

    View Physician Profile
     
     

    Research Department

    Radiation Oncology

    Interests

    Breast cancer, Breast cancer genetics, Ductal carcinoma in situ (DCIS), Thoracic malignancies

    Area of Research

    Clinical Research in Breast Cancer

    Dana-Farber Cancer Institute
    450 Brookline Avenue
    Dana Level L2
    Boston, MA 02215

    Research

    Clinical Research in Breast Cancer

    The treatment of early-stage breast cancer with conservative surgery and radiation therapy has evolved over the past several years. More attention has been paid to minimizing treatment in order to minimize toxicity. In selected patients with favorable characteristics, axillary surgery (either axillary dissection or sentinel node biopsy) may be omitted, with the intent to include the lower axilla within the standard breast radiation fields. We previously published our retrospective experience with this approach, and are in the process of reporting our prospective experience.

    Effect of radiation therapy on breast reconstruction.
    More breast cancer patients are being considered for postmastectomy radiation therapy, given the recent data suggesting a benefit in patients with positive lymph nodes. In addition, plastic surgical technique has continued to improve over the years, and more patients are electing reconstructive procedures - either simultaneous with the mastectomy or afterwards. However, radiation therapy increases the risk of complications and may alter the ultimate cosmetic result. We are reporting our retrospective experience with breast reconstruction and radiation therapy and plan to explore this issue further in a prospective study.

    Ductal carcinoma in situ.
    The management of limited ductal carcinoma in situ (DCIS) is controversial. Researchers are interested in trying to define a subgroup of patients who might be managed safely with excision alone, rather than the standard of excision plus radiation therapy. Our prospective trial closed prematurely due to an unacceptably high rate of local recurrence in carefully selected patients with ostensibly favorable DCIS. We are considering exploring the role of hormonal therapy and concurrent radiation therapy for limited DCIS.

    In summary, our main focus is clinical research in breast cancer over a broad range of topics. These projects aim to improve breast cancer treatment by optimizing outcomes with respect to tumor control while minimizing the toxicity of radiotherapy.

    Select Publications

    • Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med 2004;350:1430-41.





    • Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. Int J Radiat Oncol Biol Phys 2005;61:348-57.
    • Partridge AH, Wong JS, Knudsen K, Gelman R, Sampson E, Gadd M, Bishop KL, Harris JR, Winer EP. Offering participants results of a clinical trial: sharing results of a negative study. Lancet 2005;365:963-4.
View Researcher Directory
View Nurse Directory

Find a Clinical Trial

Support Cancer
Research

Give Now